Comparison of the Immunogenicity and Safety of Two Pediatric TBE Vaccines Based on the Far Eastern and European Virus Subtypes

Mikhail F. Vorovitch,1,2 Galina B. Maikova,1 Liubov L. Chernokhaeva,1 Victor V. Romanenko,3 Galina G. Karganova,1,2 and Aydar A. Ishmukhametov1,2

1Federal State Budgetary Scientific Institution “Chumakov Federal Scientific Center for Research and Development of Immune-and-biological Products of Russian Academy of Sciences” (FSBSI “Chumakov FSC R&D IBP RAS”), 108819 Moscow, Russia
2Sechenov First Moscow State Medical University, 119991 Moscow, Russia
3Federal Budgetary Healthcare Institution “Center for Hygiene and Epidemiology in the Sverdlovsk Region”, 620078 Yekaterinburg, Russia

Correspondence should be addressed to Liubov L. Chernokhaeva; dec151ll@mail.ru

Received 17 June 2019; Revised 12 September 2019; Accepted 5 November 2019; Published 24 December 2019

Academic Editor: Subhash C. Verma

Copyright © 2019 Mikhail F. Vorovitch et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Up to 10,000 cases of tick-borne encephalitis are registered annually, 20% of which occur in children under 17 years of age. A comparison of the immunogenicity and safety between a new pediatric Tick-E-Vac vaccine based on the TBEV strain Sofjin and FSME-IMMUN Junior vaccine was performed in the Sverdlovsk region. The vaccine strains differ from strains of the Siberian subtype of TBEV that dominates in the region. The study was performed on 163 children aged 1 to 15, who received one of the vaccines according to either a conventional or rapid vaccination schedule. Immunogenicity was assessed based on the seroprotection rates and titers of virus-neutralizing antibodies. There were no significant differences in either the immunogenicity or reactogenicity of the pediatric vaccines based on strains of the Far Eastern or European subtypes of TBEV. Under both vaccination schedules, 30 days after the second injection, seroprotection rates were 100% for Tick-E-Vac and greater than 95% for FSME-IMMUN Junior, while the geometric mean titer of TBEV-neutralizing antibodies was at least 2,4 log10 (1:250) for either vaccine. Fourteen days after the second injection according to the rapid schedule, seroprotection rates were significantly lower, ranging from 50% to 63% regardless of the vaccine used. The observed adverse reactions were mild or moderate for both vaccines under both vaccination schedules, with total adverse event rates of less than 25%. Reactogenicity was not associated with the gender or age of the recipients. There were no statistically significant differences in the incidence of adverse reactions between the group of subjects who were baseline seronegative or seropositive. However, 14 days after the second vaccine injection according to the rapid schedule, a statistically significant difference in nAbs titers was identified between groups of children with and without reported reactions.

1. Introduction

Tick-borne encephalitis (TBE) is a widespread infection in Central, Northern, and Eastern Europe, the Russian Federation, northern China, Mongolia, and Japan, with approximately 10,000 cases reported annually in the past decade [1]. More than 61 million people live in TBE-endemic regions of the Russian Federation [2], and at present, approximately 3,000 cases of this disease are registered each year. The geographic distribution of TBE is constantly increasing, and the incidence observed in children younger than 17 years has been rising, currently reaching 20% of the
2. Materials and Methods

2.1. Vaccines. Tick-E-Vac (dose 0.25 ml, batch No. 6.2009) contains purified formaldehyde-inactivated virions of the FE strain Sofjin, adsorbed on aluminum hydroxide. In brief, TBEV was propagated in primary chicken embryo fibroblast culture, inactivated, concentrated, and purified by exclusion gel chromatography. According to the manufacturer’s data, the protein E content in a vaccine dose is 0.45 ± 0.05 μg. The commercially available FSME-IMMUN Junior vaccine based on the Eur strain Neueldoerfl (dose 0.25 ml, in a prefilled syringe, batch VNR1J08D) manufactured by Baxter Vaccine AG, Austria, was used as a comparison drug. According to the manufacturer’s instruction, the protein E content in a vaccine dose is 1.19 μg.

2.2. Vaccination. The reactogenicity and immunogenicity of the study vaccines were evaluated using the results of clinical trials conducted in the municipal institution “Children’s Hospital No. 11” in Yekaterinburg, Russia. The study was monocentric, randomized, comparative, double-blind, controlled and performed in accordance with ICH-GCP and in line with the Declaration of Helsinki, including amendments (1996) and Federal Law No. 86-fz On Medicines. The study protocol (No. 0001 EIPVE version 2 dated 03/19/2010, phase III) and other documents requiring preliminary review were approved by the Ethics Committee of the Ministry of Health of the Russian Federation and the local ethics committee of the municipal institution “Children’s Hospital No. 11.” Children of either sex aged 1–15 years were enrolled in the study.

Written informed consent for study participation was obtained from the parents/legal representatives of all subjects prior to their involvement in any study procedures. Inclusion criteria were as follows:

- Healthy children of both genders
- Aged 1–15 years (from their 1st birthday to the day before their 16th birthday)
- Who had not contacted TBEV
- Who had not received an earlier vaccination against any flavivirus infection
- Who did not receive systemic therapy at the time of the study
- Who did not have any limitations or contraindications according to the instructions for vaccine use

The immunization was performed for 1 month. All subjects eligible for inclusion in the present study received two doses of either pediatric TBE vaccine on the respective days of the applicable immunization schedule, i.e., the interval between vaccine doses was 30 days (conventional schedule) or 14 days (rapid schedule). The Tick-E-Vac was administered by intramuscular injection in the M. deltoideus twice with the intervals described above. FSME-IMMUN Junior was administered in the M. deltoideus for children over 18 months, but in the M. vastus lateralis for children younger than 18 months.

2.3. Reactogenicity. Following vaccination, subjects were observed for at least 30 min as a precautionary measure in case of immediate postvaccination reactions. The following adverse reactions were recorded by doctors daily for 7 days after each injection: (1) local reactions—itching, burning sensation, local pain (at the injection site), skin reactions (redness, erythema), swelling or tightening at the injection
site, swelling of axillary lymph node on the injection side; (2) systemic reactions—fever (measured 2 times a day), sleep disturbances (insomnia) and restlessness in children aged 1–4 years, and a feeling of physical discomfort: chills, nausea, myalgia, arthralgia, vomiting, anorexia, headache, fatigue, anxiety, dizziness, and unsteady gait. Body temperature was measured rectally in children aged <3 years and by axillary thermometer in children aged ≥ 3 years, as well as in adolescents. Any fever that occurred in temporal association with vaccination (i.e., within 7 days) was included in the analysis.

Furthermore, the incidence and severity of unexpected adverse events were reported after the first injection and within 30 days following the second injection.

The process was considered to be asymptomatic if no reactions were observed in the recipient and the body temperature remained within the normal range. A scoring system was applied to assess the severity of the objective and subjective parameters. Observed adverse reactions (i.e., systemic and local reactions) were divided into the following categories:

1. Mild reactions or body temperature of up to 37.0 °C
2. Moderate reactions or body temperature of 37.1–37.5°C
3. Severe reactions or body temperature of 37.6 °C or higher

2.4 Serum Samples. Blood samples were drawn on the following days: day 0 before the first vaccine injection and day 30 after the second vaccine injection according to the conventional schedule and days 14 and 30 if the rapid schedule was used. Collected serum samples were frozen and later stored at temperatures of −20 ± 1°C until a plaque reduction neutralization test was performed. Sera on day 0 were screened by ELISA using commercial kit (VectoTBE-IgG, D-1156 Vector-Best, Novosibirsk, Russia) [11]. In brief, TBEV antibody titer in the serum was assessed according to a calibration curve of the dependence of the optical density on the IgG concentration (U/ml). IgG concentration of 100 U/ml corresponds to a titer of 1:100, 200 U/ml to a titer of 1:200, etc. And in this study, we describe the results for the primarily seronegative recipients according to the ELISA assay.

2.5 50% Plaque Reduction Neutralization Test (PRNT50). The PRNT50 analysis was conducted using the Sofjin strain of TBEV (GenBank KC806252) and pig embryo kidney cells (PEK) as previously described [9].

2.6 Statistical Analysis. Statistical analysis was performed by standard methods of variance statistic in Microcal Origin 8.0. Since the number of subjects in the groups was relatively small and the obtained data were not normally distributed, the significance of the differences between variables was determined using the Mann–Whitney test (MWT) and the chi-square test (CST). A p value of 0.05 was considered significant.

3. Results

3.1 Demographic and Anthropometric Data of the Recipients. In this study, we analyzed the data only for those subjects of the clinical study for whom full local and systemic reaction data were available and for whom serum samples were collected before and after vaccination and could be tested by PRNT50. Two hundred and twelve children who were eligible for the present study and found to be seronegative based on ELISA results were randomized into two groups and received one of the two vaccines. Thus, 152 participants would be vaccinated according to the conventional schedule (CS) and 60 according to the rapid schedule (RS); however, 49 subjects refused to participate in the study before or after the second injection and were excluded from further study.

The participant's serum samples collected on day 0 before the first vaccine injection were tested for the presence of antiviral antibodies by PRNT50, and TBEV-neutralizing antibodies (nAbs) at a titer ≥1:10 were observed in 17 (11.6%) children aged 1.3–15 years. Thereafter, the data obtained for this group of recipients were studied separately.

Of the 146 recipients who did not possess TBEV nAbs at baseline, 76 children were vaccinated with Tick-E-Vac (including 49 children—according to CS and 27—according to RS) and 70 children received FSME-IMMUN Junior (42 according to CS and 28 children according to RS). Table 1 summarizes the demographic and anthropological characteristics of the study participants, all of whom were Caucasian. As 49 (23.1%) subjects were excluded in the study after randomization, groups receiving Tick-E-Vac or FSME-IMMUN Junior according to the conventional schedule differed slightly in anthropometric features.

3.2 Reactogenicity Profile of "Tick-E-Vac" and "FSME-IMMUN Junior." The adverse reactions following TBE immunization were recorded for both vaccines. All subjects who developed local or systemic signs and symptoms were examined by medical practitioners, and no criteria for the severe unexpected adverse events were found. All reactions resolved without any intervention. In total, local and systemic reactions were registered in 32 (21.9%) children after the first injection and in 15 (10.3%) children after the second one (Table 2). For comparison, 23 (15.1%) cases of adverse reactions were seen in children who received Tick-E-Vac and 24 (17.1%) cases of adverse reactions in children who received FSME-IMMUN Junior. Differences in the incidence of adverse reactions between the vaccines were statistically insignificant (CST).

Adverse reactions after the first and second immunizations were reported in 23 (15.8%) recipients after vaccination according to CS and in 12 (8.2%) children after vaccination according to RS, corresponding to 24% of all cases of vaccine administration. The reactions following both injections were identified in 18 girls and 17 boys aged 1.1–15 years and were often observed in the same subject.
Overall, 72 reactions were registered, including 28 local reactions (such as itching, burning sensation, pain, swelling, and hyperemia at the injection site) and 44 systemic reactions (such as bodily discomfort, fever, and sleep disturbance). In total, 48 reactions occurred after the first injection and 24 reactions occurred after the second injection. In general, either local or systemic reactions were reported in children receiving either the first or the second dose of study vaccines; the number of recipients who experienced reactions of both types was significantly lower.

The following reactions were reported most frequently: a feeling of physical discomfort in 27.8%; itching, burning sensation, and local pain at the injection site in 22.2%; sleep disturbance in 18.1%; swelling at the injection site and redness in 16.7%; and fever in 15.2%. The characteristics of the reactions observed in the recipients are presented in Table 3. Differences related to the incidence, severity, and duration of local and systemic reactions between the groups receiving either Tick-E-Vac or FSME-IMMUN Junior were not statistically significant (CST).

3.3. Immunogenicity of Tick-E-Vac or FSME-IMMUN Junior. The PRNT50 test with the application of the titration method of the recipient's serum and TBEV strain Sofjin was used to evaluate the immunogenicity of the vaccines (Table 4). For seropositive children, the range of nAbs titers was from 1:10 to 1:2000. Since the obtained data were not normally distributed, the Mann–Whitney test (MWT) and the chi-square test (CST) were used to perform statistical data analysis.

In the 30 days after the second injection, seroprotection rates (SRs) in the subjects given either vaccine according to the conventional or rapid schedule were over 95%. There were no statistically significant differences identified in the

---

Table 1: Demographic and anthropological characteristics of the study groups.

| Characteristics | Parameter | Conventional schedule | Rapid schedule |
|-----------------|-----------|------------------------|----------------|
|                 |           | Tick-E-Vac | FSME-IMMUN Junior | Tick-E-Vac | FSME-IMMUN Junior |
| Number of subjects | Total number (N = 146) | 49 | 42 | 27 | 28 |
| Gender | Female/male | 23/26 | 19/23 | 11/16 | 11/17 |
| Age (years) | Mean | 7.4a | 4.7b | 4.5 | 4.0 |
| | Median | 7.0 | 3.0 | 5.0 | 4.0 |
| | Range | 1–15 | 1.1–15 | 3–6 | 1.5–9 |
| Height (cm) | Mean | 124.2b | 107.1b | 109.7 | 103.9 |
| | Median | 122.0 | 100 | 110.0 | 105.5 |
| | Range | 77–176 | 75–165 | 94–126 | 81–132 |
| Weight (kg) | Mean | 28.2c | 20.5c | 17.9 | 16.6 |
| | Median | 24.6 | 15.6 | 18.0 | 16.6 |
| | Range | 8.2–60 | 10.2–53 | 14.1–24.5 | 9.9–24 |

a,b,cStatistically significant differences of age, height, and weight between two groups of subjects who received Tick-E-Vac or FSME Immune injection according conventional schedule (MWT).

Table 2: Adverse reactions after vaccination with Tick-E-Vac or FSME-IMMUN Junior.

| Schedule | Tick-E-Vac | FSME-IMMUN Junior |
|----------|------------|--------------------|
|          | N | n | % | N | n | % |
| After the first dose administered | | | | | | |
| Conventional | 49 | 10 | 20.4 | 42 | 11 | 26.2 |
| Rapid | 27 | 6 | 22.2 | 28 | 5 | 17.9 |
| In total for the two schedules | 76 | 16a | 21.1 | 70 | 16b | 22.9 |
| After the second dose administered | | | | | | |
| Conventional | 49 | 6 | 12.2 | 42 | 7 | 16.7 |
| Rapid | 27 | 1 | 3.7 | 28 | 1 | 3.6 |
| In total for the two schedules | 76 | 7a | 9.2 | 70 | 8b | 11.4 |
| In total after both doses of vaccine administered | | | | | | |
| Conventional | 49 | 11 | 22.4 | 42 | 12 | 28.6 |
| Rapid | 27 | 7 | 25.9 | 28 | 5 | 17.9 |
| In total for the two schedules | 76 | 18 | 23.7 | 70 | 17 | 24.3 |

N—total number of subjects; n—number of subjects who developed the adverse reactions. a,bStatistically significant differences of reverse reactions after the first injection and after the second one (CST).
SRs (CST) and nAbs titers (MWT) between groups of children vaccinated with either Tick-E-Vac or FSME-IMMUN Junior. Differences found in the SRs and nAbs titers were not statistically significant across the groups of children who had received two doses according to conventional or rapid vaccination schedules, and there were no significant differences in geometric mean titer of TBEV nAbs (GMTA) between the groups.

However, 14 days after the second dose was administered, the SRs determined in children vaccinated according to the rapid schedule with Tick-E-Vac or FSME-IMMUN Junior were only 63% and 50%, respectively. In this case, GMTA was 1:40 for seropositive children who received Tick-E-Vac and 1:60 for those who received FSME-IMMUN Junior. The difference between nAbs titers measured on 14th and those measured on the 30th day were statistically significant for both vaccines ($p = 0.001$, MWT).

We assessed the correlation between groups regarding nAbs titers and ages of the total group of subjects vaccinated with either vaccine according to both a conventional or rapid schedule. The correlation coefficient values ranged from −0.2 to 0.2, which were applicable for both vaccines and for all time intervals at which the serum samples were analyzed. It was also determined that the SRs and nAbs titers (CST and MWT, accordingly) in children in the age groups 1–4 (64 children), 5–11 (68 children), and 12–15 (14 children) years were not significantly different from each other.

3.4. Analysis of the Relationship between the Immunogenicity and Reactogenicity of the TBE Vaccines. To examine the relationship between reactogenicity and immunogenicity of vaccination against TBE after two doses according to the conventional or rapid schedule, we compared SRs, nAbs

### Table 3: Characteristics of local and systemic reactions in children vaccinated with Tick-E-Vac and FSME-IMMUN Junior.

| Vaccination  | Reaction | Vaccine (T, I) | Number of subjects (%) | Severity* | Onset interval (days) | Duration (days) |
|--------------|----------|----------------|------------------------|-----------|----------------------|-----------------|
| Conventional schedule |
| 1 Local T | 7/14.3 | 1 | 1 | 1-2 |
| I | 8/19.0 | 1-2 | 1 | 1-3 |
| | 6/12.2 | 1-2 | 1 | 1-3 |
| Systemic T | 10/23.8 | 1-2 | 1-2 | 1-3 |
| 2 Local T | 3/6.1 | 1-2 | 1-3 | 1 |
| I | 2/4.8 | 1 | 1 | 2 |
| Systemic T | 5/10.2 | 1-3 | 1-3 | 3 or more |
| | 11/26.2 | 1-2 | 1-2 | 3 or more |
| Rapid schedule |
| 1 Local T | 2/7.4 | 1 | 1 | 1 |
| I | 5/17.9 | 1 | 1 | 2 |
| Systemic T | 6/22.2 | 1-2 | 1-2 | 1-4 |
| | 4/14.3 | 1 | 1 | 1-2 |
| 2 Local T | — | — | — | — |
| I | 1/3.6 | 1 | 1 | 3 |
| Systemic T | 2/7.4 | 1 | 2 | 2 |

T, Tick-E-Vac; I, FSME-IMMUN Junior. *Severity scores (see Materials and Methods).

### Table 4: Immunogenicity of Tick-E-Vac and FSME-IMMUN Junior.

| Schedule | Vaccine | Blood sampling | N | SRs, % | GMTA, log_{10} |
|----------|---------|----------------|----|--------|----------------|
| CS       | Tick-E-Vac | 30 days after administration of the second dose | 49 | 100 | 2.5 (1.0–3.3) |
|          | FSME-IMMUN Junior |                   | 42 | 95.2 | 2.4 (0.3–3.3) |
|          | Tick-E-Vac | 14 days after administration of the second dose | 27 | 63 | 1.0 (0.3–3.3) |
|          | FSME-IMMUN Junior |                   | 28 | 50 | 0.9 (0.3–3.3) |
|          | Tick-E-Vac | 30 days after administration of the second dose | 27 | 100 | 3.1 (1.1–3.3) |
|          | FSME-IMMUN Junior |                   | 28 | 96.4 | 2.4 (0.3–3.3) |

CS: conventional schedule; RS: rapid schedule; N: total number of subjects in the groups; GMTA: geometric mean titer of TBEV-neutralizing antibodies; M: median; (): nAbs titer range; a,b,c,d: difference between the nAbs titers measured on day 14 and those measured on day 30 after immunization according to rapid schedule (MWT).
titers, and GMTA in two combined groups. The first group consisted of subjects who developed adverse reactions after receiving either vaccine, and the second group included subjects who had no reported adverse reactions (Table 5). The differences in the SRs and nAbs titers between the two groups were statistically insignificant on day 30 after the second dose was administered. However, for the rapid vaccination schedule on day 14 following the administration of the second dose, a comparison between sera from subjects who had no reactions and those who developed reactions revealed differences in the nAbs titers \( (p = 0.00752, \text{MWT}) \). GMTA was \( 2.3 \log_{10} (1:182) \) in the group of subjects who developed adverse reactions, but only \( 1.5 \log_{10} (1:32) \) in the group of subjects who had no reactions.

3.5. Reactogenicity and Immunogenicity of Tick-E-Vac or FSME-IMMUN Junior in Participants with nAbs to TBEV before Vaccination. In this group, TBEV nAbs titers ranged from 1.0 to 3.3 \( \log_{10} \) before the first dose of vaccine was given. The GMTA \( 1.6 \log_{10} \) values were determined in the serum samples collected from 17 children (11.6%) (7 girls and 10 boys) aged 1.3 to 15 years.

Local and systemic reactions after the first vaccine injection were observed in 5 children (29.4%) in this group, and 3 (17.6%) of them developed the reactions after the second one. At the same time, the differences between the incidences of adverse reactions reported in this group and in the group of subjects who were seronegative at baseline (21.9% after the first injection and 10.3% after the second, Table 2) did not reach statistical significance. The most frequently reported reactions were as follows: itching, burning sensation, and local pain at the injection site—17.6%; sleep disturbance—17.6%; a feeling of bodily physical discomfort—11.8%; fever—5.9%; and swelling at the injection site and redness—5.9%. All reported reactions were mild, occurred within 1–3 days after vaccination, and lasted no more than 3 days.

The administration of either vaccine according to any schedule led to an increased titer of nAbs against TBEV, and the GMTA identified in this initially seropositive group of subjects was \( 2.2 \log_{10} (1:158) \). On day 30 after the second injection, no statistically significant differences in immunogenicity (SRs and nAbs titers) were identified in the group who were either seronegative or seropositive at baseline.

4. Discussion

In the Russian Federation, a licensed domestic vaccine intended for the immunization of young children (aged 1 to 3 years) was not available until 2012. For this reason, imported vaccines based on the European strains of TBEV were used for this population. Data regarding the reactogenicity and immunogenicity of such vaccines used in areas in which Eur subtypes of TBEV circulate have been previously published [7].

A new liquid adsorbed TBE vaccine (Tick-E-Vac) based on the FE strain Sofjin was developed in Chumakov Federal Scientific Center. The vaccine contains purified formaldehyde-inactivated virions, adsorbed on aluminum hydroxide. The vaccine contains no formaldehyde, antibiotics, and preservatives. There are two forms of the vaccine: for persons 16 years old and up in a dose 0.5 ml and for children and adolescents at a dose 0.25 ml. The primary vaccination course for this vaccine consists of two intramuscular injections given according to the conventional or rapid schedule. The interval between injections is from 1 to 7 months (conventional schedule) or 14 days (rapid schedule). The vaccination course could be performed year-round including epidemic season, but not later than 2 weeks before time of visit to TBE natural focus. First revaccination is performed in 1 year after completion of primary vaccination course; subsequent booster vaccinations are carried out every 3 years. Tick-E-Vac can also be used for immunization of blood donors.

The primary course of immunization against TBE should induce antiviral antibodies in protective titers of at least 95% in vaccinated subjects, i.e., provide sufficient protection to allow patients to live in TBE-endemic areas. The primary vaccination course for all TBE vaccines produced in Russia, including the Tick-E-Vac, consists of only two injections followed by revaccinations. Although FSME-IMMUN Junior primary vaccination consists of three injections, the vaccine provides acceptable immunogenicity even by a double immunization schedule [7]. Accordingly, when choosing a vaccine for comparison in the clinical study involving Tick-E-Vac and having only two injections as immunization schedule, FSME-IMMUN Junior, which is known for its low adverse event rates and high immunogenicity was chosen as a comparison drug.

Evaluations of the reactogenicity and immunogenicity of whole virion, inactivated, and concentrated vaccines against TBE have been conducted repeatedly; however, the majority of these studies analyzed collected immunization data corresponding to the conventional vaccination schedule [12–14] or the rapid schedule [15–17]. Data from comparative studies of reactogenicity and immunogenicity of different TBE vaccines using different immunization schedules in a single experiment were rather limited [18].

In this study, we evaluated and compared the reactogenicity profiles and effectiveness of the pediatric version of two vaccines: Tick-E-Vac and FSME-IMMUN Junior. Tick-E-Vac is based on the FE subtype of TBEV and FSME-IMMUN Junior is based on Eur subtype; thus, the TBEV strains used to produce the vaccines differ from strains of the Sib subtype of TBEV which is currently dominating in the Sverdlovsk region [10] in which this study was performed.

As shown previously, the vaccines based on the FE strain Sofjin or Eur strain Neudoerfl of TBEV are characterized by a pronounced immunogenicity based on the antiviral antibody titers, as measured by the enzyme-linked immune sorbent assay (ELISA) [11]. However, data obtained using only the ELISA method do not allow the evaluation of the full degree of protection of the recipients [19, 20].

According to the Russian Ethical Guidelines for clinical trials, individuals living in TBE-endemic areas usually participate in clinical studies with TBE vaccines. A number of works have shown that the level of naturally acquired immunity against TBEV in such regions can account for more than 20% [15, 20]. In the course of the study, we also identified a significant number of children between the ages
of 1.3 and 15 who were TBE seropositive based on the PRNT50 results (11.6%, GMTA—1.6 log10), but who either did not have a history of TBE infection, had not been vaccinated against TBE, or were seronegative according to the ELISA results. The data on the reactogenicity and immunogenicity registered in these subjects can be significantly distorted by a high level of naturally acquired immunity [21]. Therefore, in the current work, we focused on the analysis of the data obtained from participants who were seronegative before immunization, according to the results obtained by both methods described above (PRNT50 and ELISA). Children were screened by ELISA using VectoTBE-IgG kit. This kit is designed to determine specific antibodies to various subtypes of TBEV and is usually used to assess the immunogenicity of TBE vaccines in Russia [11, 12, 22].

The analysis of reactogenicity of Tick-E-Vac and FSME-IMMUN Junior showed that local and systemic reactions reported in children were mild or moderate. These reactions usually occurred 1-2 days after immunization and lasted no more than 3-4 days. The incidence of these reactions for either vaccine was statistically lower after the second dose was given. Although groups vaccinated with Tick-E-Vac or FSME-IMMUN Junior differed in some anthropometric features (Table 1), there were no statistically significant differences in the reactogenicity of the vaccines. The reactogenicity did not correlate with the gender or age of the subjects either.

According to the manufacturer’s data, the protein E content is 0.45 ± 0.05 μg per Tick-E-Vac dose and 1.19 μg per dose of FSME-IMMUN Junior. There were no differences in the reactogenicity profiles relative to the amount of protein E per vaccine dose, although one should keep in mind that the manufacturers use different methods for the measurement of protein E.

The PRNT50 method was applied to evaluate immunogenicity using the Sofjiñ strain of TBEV as the challenge virus. It could be expected to influence the value of nAbs titer in sera collected from subjects immunized with FSME-IMMUN Junior and resulted in lower nAbs titers than the ones for Tick-E-Vac immunized children. But, any statistically significant differences in the immunogenicity of the studied vaccines were not demonstrated. These data are in good agreement with the data for protective efficacy TBE vaccines based on Eur or FE strains against various TBEV strains in vivo and in vitro [23–26]. It was demonstrated that GMTA was at least 2.4 log10 (1:250) in the 30 days after the second dose of either vaccine, suggesting that a pronounced immune response is formed and that a protective titer of antiviral nAbs exists. We calculated SR as the percentage of recipients with nAbs titers greater than 1:10, values that are usually taken as protective titers against TBE [7]. On day 30 after the second dose was administered, the seroprotection rates were 100% for Tick-E-Vac and more than 95% for FSME-IMMUN Junior. These values did not correlate with the applied immunization schedule. Although groups vaccinated with Tick-E-Vac or FSME-IMMUN Junior differed in some anthropometric features, the difference did not affect immunogenicity.

It should be noted that seroprotection rates were significantly lower on day 14 after the administration of the second dose according to the rapid vaccination schedule, ranging from 50% to 63%, regardless of the vaccine used. Thus, these results should be taken into account when vaccinating children under 16 years old, as they reach the maximum level of seroprotection later than adults, in whom SRs of at least 90% are registered in two weeks after receiving the second dose [27]. Since the probability of previous interactions with TBEV in adults is higher than in children [20], these differences may be associated with higher levels of immunological memory in adults living in TBE-endemic areas than in children living in the same areas, even if recipients are initially seronegative according to data of ELISA and PRNT50.

As for conventional and rapid primary immunization schedules, we did not reveal statistically significant differences in SRs and in antiviral nAbs titers in the 30 days after the second dose was administered, allowing us to begin discussion with respect to transitioning to a universal (single) schedule for primary vaccination against TBE, corresponding to the 0- to 14-day schedule. However, it is necessary to assess long-term immune responses in vaccinated individuals and determine whether a solid immunological memory has built up. Likewise, there was no correlation between the immunogenicity profile and the children’s gender and age.

According to Leonova et al., there was a possible correlation between high titers of antibodies against TBEV in subjects who received the vaccine and the incidence and severity of local and systemic reactions due to TBE vaccination reported [21]. Our study demonstrated that SRs, determined at different time intervals after the second dose was administered, did not differ between the combined groups of subjects, who developed adverse reactions after injection with either vaccine or those who had no reactions (Table 5). At the same time, a statistically significant difference between these groups in the antiviral nAbs titers,

### Table 5: Relationship between immunogenicity and reactogenicity of the TBE vaccines.

| Schedule   | Subjects | Number of subjects | Immunogenicity* (after 2 doses) |
|------------|----------|-------------------|-------------------------------|
|            |          |                   | 14 days                      | 30 days                      |
| Conventional |          |                   | nd                           | nd                           |
|            | With reactions | 23                | 95.7/2.2 (1.1–3.3)            | 66.7/2.3* (1.3–3.3)          |
|            | With no reactions | 68                | 98.5/2.6 (1.0–3.3)            | 100/2.8 (1.6–3.3)            |
| Rapid      |          |                   | nd                           | nd                           |
|            | With reactions | 12                | 53.5/1.9* (1.0–3.3)           | 97.7/2.8 (1.1–3.3)           |
|            | With no reactions | 43                | 66.7/2.3* (1.3–3.3)           | 100/2.8 (1.6–3.3)            |

* Numerator, SRs; denominator, GMTA. ( ), nAbs titer range; nd, not determined. *Difference in nAbs titers (MWT).
registered on day 14 after the second dose was given according to the rapid vaccination schedule, were identified, which may indicate a faster increase in nAbs titer in recipients who developed local or systemic reactions. However, it should be noted that the compared groups substantially differed in the number of participants.

We also evaluated the reactogenicity and immunogenicity in subjects who initially possessed antiviral nAbs titers. Overall, 72 local and systemic reactions (9.9% of the total number) were registered in the baseline seronegative recipients, and 10 reactions (5.9%) were registered in the baseline seropositive subjects. There were no statistically significant differences between these two groups of recipients with regard to reactogenicity. In the 30 days after the second injection, the differences in SRs and nAbs titers were not statistically significant either.

Thus, the obtained data on the incidence, severity, and duration of local and systemic reactions in children, who for the first time received Tick-E-Vac or FSME-IMMUN Junior according to the conventional or rapid vaccination schedule, suggest acceptable reactogenicity for both vaccines studied. High rates of immunogenicity of the TBE vaccines studied were demonstrated as well. At the same time, any statistically significant differences in the reactogenicity or immunogenicity of the studied vaccines based on strains of the FE or Eur TBEV subtypes have not been determined.

5. Conclusions

The obtained data suggest acceptable reactogenicity and high immunogenicity of the pediatric form of Tick-E-Vac and FSME-IMMUN Junior. The observed adverse reactions were mild or moderate for both vaccines and were not associated with the gender or age of the recipients. Under conventional and rapid vaccination schedules, in the thirty days after the second injection, the two-dose primary immunization induced protective titers of TBEV neutralizing antibodies in protective titers in at least 95% of vaccinated subjects. At the same time, any differences in the reactogenicity or immunogenicity of the studied vaccines based on strains of FE or Eur TBEV subtypes have not been demonstrated in children living in the region in which strains of the Sib subtype of TBEV are dominating.

Data Availability

Clinical trials data are published in [11] and presented in this study. Raw protocols are available upon request.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Acknowledgments

This study was partially supported by the program of increasing the competitiveness of the leading Russian universities among the world’s leading research and educational centers. The authors thank Yu. V. Rogova for providing technical assistance in this work. The authors would also like to thank Editage (http://www.editage.com) for English language editing.

Supplementary Materials

The supplementary file is the English version of the official information for the user of Tick-E-Vac (instruction of Tick-E-Vac application in Russian). The last version of the instruction was approved on 3/16/2017. Instruction of Tick-E-Vac application includes the following: composition, immunological and biological properties, indication, contraindications, safety, application and dosage, the vaccination schedules, possible adverse reactions and vaccine overdose, pediatric and adult form description, and storage and transportation conditions. (Supplementary Materials)

References

[1] D. Ruzek, T. Avšič Županc, J. Borde et al., “Tick-borne encephalitis in Europe and Russia: review of pathogenesis, clinical features, therapy, and vaccines,” Antiviral Research, vol. 164, pp. 23–51, 2019.
[2] L. L. Chernokhaeva, I. S. Khолодилов, and N. D. Паксина, “Present distribution area of tick-borne encephalitis in the Russian Federation,” Medizinskaya Virusologiya, vol. 30, no. 1, pp. 6–22, 2016, in Russian.
[3] Russian Federal Service for Surveillance on Consumer Rights protection and human Wellbeing (Rospotrebnadzor), http://rospotrebnadzor.ru/activities/statistical-materials/statistic_details.php?ELEMENT_ID=7804.
[4] A. М. Q. King, E. Lefkowitz, M. J. Adams et al., Virus Taxonomy: Classification and Nomenclature of Viruses: Ninth Report of the International Committee on Taxonomy of Viruses, Elsevier, San Diego, CA, USA, 2012.
[5] T. V. Demina, Y. P. Dzhioev, M. M. Вихозина et al., “Genotyping and characterization of the geographical distribution of tick-borne encephalitis virus variants with a set of molecular probes,” Journal of Medical Virology, vol. 82, no. 6, pp. 965–976, 2010.
[6] A. Loew-Baselli, R. Konior, B. G. Pavlova et al., “Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies,” Vaccine, vol. 24, no. 24, pp. 5256–5263, 2006.
[7] E. М. Pöllabauer, B. G. Pavlova, А. Löw-Baselli et al., “Comparison of immunogenicity and safety between two paediatric TBE vaccines,” Vaccine, vol. 28, no. 29, pp. 4680–4685, 2010.
[8] M. F. Vorovitch, L. I. Kozlovskaya, L. И. Romanova et al., “Genetic description of a tick-borne encephalitis virus strain Sofjin with the longest history as a vaccine strain,” Springplus, vol. 4, no. 1, p. 761, 2015.
[9] L. L. Chernokhaeva, Y. V. Rogova, M. F. Vorovitch et al., “Protective immunity spectrum induced by immunization with a vaccine from the TBEV strain Sofjin,” Vaccine, vol. 34, no. 20, pp. 2354–2361, 2016.
[10] S. Iu. Kovalev, T. V. Umpeleva, T. Е. Снитковская et al., “Molecular and epidemiological characteristics of tick-borne encephalitis virus in the Sverdlovsk Region on the basis of genotype-specific RT-PCR,” Voprosy Virusologii, vol. 53, no. 2, pp. 27–31, 2008, in Russian.
[11] V. Ankudinova, V. V. Romanenko, M. F. Vorovitch et al., “Results of a clinical immunogenicity and safety trial of
“Tick-E-Vac” 0.25 ml vaccine (pediatric dosage),” *Journal of Ural Medical Academic Science*, vol. 51, no. 5, pp. 64–69, 2014, in Russian.

[12] A. Loew-Baselli, E. M. Poellabauer, B. G. Pavlova et al., “Prevention of tick-borne encephalitis by FSME-IMMUN vaccines: review of a clinical development programme,” *Vaccine*, vol. 29, no. 43, pp. 7307–7319, 2011.

[13] E. V. Pavlenko, G. N. Leonova, and O. S. Maystrovskaya, “Comparative study of the immunogenicity of vaccines against tick-borne encephalitis,” *Far East Medical Journal*, vol. 11, no. 11, pp. 56–62, 2007, in Russian.

[14] V. Feldblum, I. A. Okuneva, T. V. Danilina et al., “Assessment of reactogenicity, safety and immunogenicity of the domestic vaccine ‘EnceVir’ with the reduced antigenic load in the immunization of children aged 3-17 years accordingly to routine scheduled vaccination (report 2),” *Epidemiology and Infectious Diseases*, vol. 20, no. 3, pp. 28–32, 2015, in Russian.

[15] N. A. Shoutova, O. V. Shkouratova, Ye. V. Rouzavina et al., “Studying immunologic activity and reactogenicity ‘EnceVir’ vaccine immunization using express-scheme,” *Sibirskii Medicinskii Zhurnal*, vol. 24, no. 2, pp. 30–33, 2009, in Russian.

[16] M. S. Vorobjeva, L. P. Ladizhenskaya, O. A. Barhaleva et al., “Immune response during rapid immunization against tick-borne encephalitis vaccine Encevir (Russia) and FSME-Immune (Austria),” *Epidemic, vol. 5*, no. 48, pp. 61–65, 2009, in Russian.

[17] V. Feldblum, M. G. Menshikova, T. V. Danilina et al., “Evaluation of reactogenicity, safety and immunogenicity of domestic vaccine ‘EnceVir’ with a reduced antigen load in immunization of children 3–17 year old accordingly to emergency vaccination protocol,” *Epidemiology and Infectious Diseases*, vol. 4, pp. 53–57, 2013, in Russian.

[18] A. Domnich, D. Panatto, E. K. Arbuzova et al., “Immunogenicity against Far Eastern and Siberian subtypes of tick-borne encephalitis (TBE) virus elicited by the currently available vaccines based on European subtype: systematic review and meta-analysis,” *Human Vaccines and Immunotherapeutics*, vol. 10, no. 10, pp. 2818–2833, 2014.

[19] L. L. Chernokhaeva, G. B. Maikova, Yu. V. Rogova et al., “Comparison of results obtained in ELISA and neutralization test in assessment of the protection of population from tick-borne encephalitis,” *Voprosy Virusologii*, vol. 63, no. 1, pp. 36–40, 2018, in Russian.

[20] G. B. Maikova, L. L. Chernokhaeva, Y. V. Rogova et al., “Ability of inactivated vaccines based on Far-eastern tick-borne encephalitis virus strains to induce humoral immune response in originally seropositive and seronegative recipients,” *Journal of Medical Virology*, vol. 91, no. 2, pp. 190–200, 2019.

[21] G. N. Leonova, N. V. Krylova, E. V. Pavlenko et al., “Reactogenicity of tick-borne encephalitis vaccine ‘Encepur adult’ and immune response,” *Medical Immunology*, vol. 7, no. 4, pp. 391–396, 2005, in Russian.

[22] P. Ladyzhenskaya, M. S. Vorobieva, K. A. Sarkisyan et al., “Detection of specific immunoglobulin G in human immunoglobulin preparations against tick-borne encephalitis virus by ELISA,” *Biopreparation (Biopharmaceuticals)*, vol. 3, pp. 26–35, 2013, in Russian.

[23] O. S. Afonina, L. L. Terekhina, O. A. Barkhaleva et al., “Experimental studies cross immune response to antigens of the virus strains of tick-borne encephalitis different genotypes in BALB/c mice, immunized with various embodiments of tick-borne encephalitis vaccine,” *Epidemiology and Prevention of Vaccine-Preventable Diseases*, vol. 78, no. 5, pp. 88–96, 2014, in Russian.

[24] R. Fritz, K. K. Orlinger, Y. Hofmeister et al., “Quantitative comparison of the cross-protection induced by tick-borne encephalitis virus vaccines based on European and Far Eastern virus subtypes,” *Vaccine*, vol. 30, no. 6, pp. 1165–1169, 2012.

[25] G. B. Maikova, L. L. Chernokhaeva, M. F. Vorovitch et al., “Vaccines based on the Far-Eastern and European strains induce the neutralizing antibodies against all known tick-borne encephalitis virus subtypes,” *Voprosy Virusologii*, vol. 61, no. 3, pp. 135–139, 2016, in Russian.

[26] L. L. Chernokhaeva, Y. V. Rogova, L. I. Kozlovskaya et al., “Experimental evaluation of the protective efficacy of tick-borne encephalitis (TBE) vaccines based on European and Far-Eastern TBEV strains in mice and in vitro,” *Frontiers in Microbiology*, vol. 9, p. 1487, 2018.

[27] M. F. Vorovitch, G. B. Maikova, L. L. Chernokhaeva et al., “Immunogenicity and safety of the adult TBE vaccine «Tick-E-Vac»,” *Voprosy Virusologii*, vol. 62, no. 2, pp. 73–80, 2017, in Russian.